Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial

Phase 4 Recruiting 100 enrolled University of Witwatersrand, South Africa Bill and Melinda Gates Foundation · collab

NaSingle-groupOpen-labelPrevention

Summary

This is a single-arm, open-label, effectiveness study designed to evaluate the use of Tenofovir, Lamivudine, and Dolutegravir in people with newly diagnosed HIV-1 infection initiating first-line Antiretroviral Therapy with Cabotegravir-Long-acting Pre-Exposure Prophylaxis exposure in the preceding 12 months. Participants will be followed up for a period of 12 months from enrolment.

Timeline

Start: 2024-06-01
Primary completion: 2026-06-30
Completion: 2026-08-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dolutegravir	Other / unclassified	50 mg	Oral
Subject	Lamivudine	Other / unclassified	300 mg	Oral
Subject	Tenofovir disoproxil fumarate	Small molecule	300 mg	Oral

Indications

No indication recorded.